H2 receptor antagonists are drugs that inhibit histamine action in the stomach, reducing acid production.

Jazz Pharmaceuticals plc announced early results from its Phase 2 trial evaluating the efficacy and safety of JZP150, a selective FAAH enzyme inhibitor, in adults with PTSD.

Drug delivery can be significantly affected by the pH of the environment in which it occurs.

The FDA has sanctioned an update to the packaging of Kite Pharma's Yescarta® treatment, now incorporating information on patient survival rates.

CGRP antagonists are drugs that block the CGRP receptor, used in preventing migraines.

WAINUA™ (eplontersen) Receives Groundbreaking US Sanction as a Treatment for Polyneuropathy in Adult Hereditary Transthyretin Amyloidosis Cases.

The solubility of a drug can significantly impact its bioavailability, absorption rate, and ultimately, its effectiveness as a therapeutic agent.

Sanofi has terminated its study of tusamitamab ravtansine due to a Phase 3 trial in second-line NSCLC failing to achieve its main goal.

D2 receptor agonists are drugs that activate the D2 subtype of dopamine receptors, used in treating conditions like Parkinson’s disease and hyperprolactinemia.

GSK plc has entered an exclusive partnership with Hansoh Pharma to co-develop and market HS-20093, an antibody-drug conjugate (ADC) targeting B7-H3 with a clinically proven topoisomerase inhibitor payload for serious medical conditions.

Prodrugs are pharmacologically inactive compounds that are converted into an active drug after administration within the body.

Aurinia Pharmaceuticals Inc. announced it filed an IND application for AUR200 with the FDA to advance its development.